Court R. Turner, J.D. is the president, CEO and director of Synthorx. He is also a venture partner at Avalon Ventures; Mr. Turner joined Avalon in 2008 as an advisor and became a venture partner in 2010. As a venture partner and serial entrepreneur, Mr. Turner has served as the president, CEO and director of Carolus Therapeutics, COO and director of Afraxis, and director of Zacharon Pharmaceuticals (acquired by Biomarin), and director at Otonomy. Additionally, Mr. Turner led Avalon’s investment and served as founding CEO and chairman for RQx Pharmaceuticals (signed exclusive deal with Genentech). He currently serves as a board observer of Cardeas Pharma. Prior to joining Avalon Ventures, he spent 11 years in leadership positions in San Diego biotech companies, including Kalypsys and Aurora Biosciences. Mr. Turner received a J.D. from the University of San Diego School of Law and B.S. in psychology from San Diego State University.